New taper-shaped cuff reduces risk of microaspiration
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 19, 2009--
Covidien (NYSE: COV), a leading global healthcare products company and
recognized innovator in mechanical ventilation and respiratory care
devices, today announced the global launch of Mallinckrodt™ TaperGuard™
and TaperGuard™ Evac endotracheal tubes. The TaperGuard line of
endotracheal tubes incorporates a unique, taper-shaped cuff made from
polyvinylchloride (PVC) that is designed to substantially reduce the
risk of microaspiration. The TaperGuard Evac endotracheal tube
additionally provides for secretion drainage through an integrated
suction lumen. As a result, the TaperGuard Evac endotracheal tube is
associated with a reduction in ventilator-associated pneumonia (VAP).
Microaspiration refers to the entry of foreign material into the
respiratory tract. The TaperGuard line of endotracheal tubes offers a
superior cuff seal, compared with conventional endotracheal tubes, to
help block secretions from entering the airways. Specifically, the
innovative taper-shaped cuff design substantially reduces
microaspiration by an average of 90%, versus the conventional
barrel-shaped PVC cuff, found on the most widely used endotracheal tube
-- the Mallinckrodt™ Hi-Lo™ endotracheal tube.2
“In the 1970’s, we introduced the Hi-Lo endotracheal tube, which has
been the standard of care for many years,” said James E. Willett, Vice
President and General Manager, Airway Management and Ventilation,
Covidien. “Today, the innovative taper-shaped cuff of the TaperGuard
endotracheal tube offers enhanced protection for all intubated patients.
The TaperGuard device is the next-generation endotracheal tube, one that
reflects our commitment to developing products that improve patient
safety by reducing microaspiration, which is associated with a variety
of pulmonary complications, including pneumonia.”
Medical literature over the past four decades suggests that
post-intubation pulmonary complications are prevalent, costly and
associated with increased morbidity and mortality. The four most
commonly cited pulmonary complications are pneumonia, respiratory
failure, atelectasis and acute exacerbation of chronic lung disease.3
Each of these complications has been associated with microaspiration of
secretions into the lungs. Studies have reported volumes of up to 150 ml
of secretions being removed per day above the cuff.4
Additional data suggests that, with conventional endotracheal tubes,
microaspiration can occur at any time from intubation to extubation.
“Microaspiration is always a possibility during an operation and may
lead to post-intubation pulmonary complications, such as pneumonia,”
said Douglas Hansell, M.D., M.P.H., Chief Medical Officer & Vice
President, Respiratory and Monitoring Solutions, Covidien. “The advanced
design of the TaperGuard endotracheal tube has the potential to
significantly minimize many of the risks associated with post-intubation
The TaperGuard Evac endotracheal tube combines the TaperGuard cuff with
Mallinckrodt Evac technology, which offers secretion management
capabilities by enabling continuous or intermittent drainage of
secretions that collect above the cuff.
“The global launch of the TaperGuard line of endotracheal tubes
illustrates Covidien’s commitment to developing innovative, proven
solutions for commonly occurring healthcare complications, with the goal
of decreasing patient mortality, as well as healthcare costs,” said Pete
Wehrly, President, Respiratory and Monitoring Solutions, Covidien. “With
each new product and technology, our goal remains the same: to enhance
patient safety, medical efficacy and healthcare efficiency,” he added.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2008 revenue of $10 billion, Covidien has more than
41,000 employees worldwide in 59 countries, and its products are sold in
over 140 countries. Please visit www.covidien.com
to learn more about our business.
1 510 (k) clearance letter.
2 510 (k) clearance letter.
3 Arozullah et al. Ann Surg. 2000;232(2):242-253.
4 Rawlinson, E. Pulmonary aspiration. Anesthesia and
Intensive Care Medicine. 2007: 8(9); 365-367.
Sherri Hughes-Smith, 303-581-6849
Manager, Media and
Respiratory and Monitoring Solutions
Lannum, CFA, 508-452-4343